Compare Aventis Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs PROCTER & GAMBLE HEALTH - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA PROCTER & GAMBLE HEALTH SANOFI INDIA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 36.1 52.7 68.6% View Chart
P/BV x 6.3 4.8 132.8% View Chart
Dividend Yield % 1.4 10.0 13.8%  

Financials

 SANOFI INDIA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
PROCTER & GAMBLE HEALTH
Dec-18
SANOFI INDIA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs6,8403,549 192.7%   
Low Rs4,6301,301 355.8%   
Sales per share (Unadj.) Rs1,203.1511.4 235.2%  
Earnings per share (Unadj.) Rs165.361.3 269.6%  
Cash flow per share (Unadj.) Rs209.974.0 283.5%  
Dividends per share (Unadj.) Rs84.00440.00 19.1%  
Dividend yield (eoy) %1.518.1 8.1%  
Book value per share (Unadj.) Rs963.6927.8 103.9%  
Shares outstanding (eoy) m23.0316.60 138.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.84.7 100.5%   
Avg P/E ratio x34.739.6 87.7%  
P/CF ratio (eoy) x27.332.8 83.4%  
Price / Book Value ratio x6.02.6 227.7%  
Dividend payout %50.8717.9 7.1%   
Avg Mkt Cap Rs m132,07840,257 328.1%   
No. of employees `0003.31.1 291.1%   
Total wages/salary Rs m4,0681,313 309.9%   
Avg. sales/employee Rs Th8,393.87,486.7 112.1%   
Avg. wages/employee Rs Th1,232.41,157.6 106.5%   
Avg. net profit/employee Rs Th1,153.0897.2 128.5%   
INCOME DATA
Net Sales Rs m27,7088,490 326.4%  
Other income Rs m897244 367.8%   
Total revenues Rs m28,6058,734 327.5%   
Gross profit Rs m6,2351,482 420.8%  
Depreciation Rs m1,027211 486.3%   
Interest Rs m70-   
Profit before tax Rs m6,0981,514 402.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m2,292563 407.5%   
Profit after tax Rs m3,8061,017 374.1%  
Gross profit margin %22.517.5 128.9%  
Effective tax rate %37.637.1 101.2%   
Net profit margin %13.712.0 114.6%  
BALANCE SHEET DATA
Current assets Rs m15,92215,343 103.8%   
Current liabilities Rs m6,2351,960 318.1%   
Net working cap to sales %35.0157.6 22.2%  
Current ratio x2.67.8 32.6%  
Inventory Days Days6449 130.6%  
Debtors Days Days2128 73.3%  
Net fixed assets Rs m7,5391,209 623.4%   
Share capital Rs m230166 138.6%   
"Free" reserves Rs m21,96215,235 144.2%   
Net worth Rs m22,19215,401 144.1%   
Long term debt Rs m00-   
Total assets Rs m29,83917,595 169.6%  
Interest coverage x872.1NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.90.5 192.4%   
Return on assets %12.85.8 221.0%  
Return on equity %17.26.6 259.6%  
Return on capital %27.510.3 268.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,5871,636 463.7%   
Fx outflow Rs m7,1454,368 163.6%   
Net fx Rs m442-2,732 -16.2%   
CASH FLOW
From Operations Rs m3,739-1,304 -286.8%  
From Investments Rs m-73112,697 -5.8%  
From Financial Activity Rs m-1,972-301 656.2%  
Net Cashflow Rs m1,03611,093 9.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 51.8 116.6%  
Indian inst/Mut Fund % 14.4 18.2 79.1%  
FIIs % 14.6 1.0 1,460.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 29.1 36.1%  
Shareholders   15,184 28,591 53.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Oct 18, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ALKEM LABORATORIES COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS